We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » AVENTIS CHANGES LABELING, DOSAGE REQUIREMENTS FOR LOVENOX
AVENTIS CHANGES LABELING, DOSAGE REQUIREMENTS FOR LOVENOX
August 19, 2004
Aventis Pharmaceuticals has revised its labeling of the drug Lovenox (enoxaparin sodium) to better inform physicians prescribing medications to patients suffering from renal impairment.